Engineered immune cells for treating cancer in combination with il-2/il-15 receptor beta-gamma agonists
AssigneeSotio Biotech Inc.
InventorsAmy JENSEN, Emily KUIPER, Kathleen WHITEMAN, Irena ADKINS
Life of this patent
Estimating the term…
Abstract
A combined therapy for treating cancer in a subject, comprising an immune cell population and an Interleukin-2/Inter-leukin-15 receptor beta gamma (IL-2/IL-15Rβγ) agonist. The immune cell population comprises genetically engineered immune cells expressing or overexpressing a metabolism-regulating polypeptide, which may (a) improves glucose uptake activity; (b) modulates the Krebs cycle; (c) enhances lactate concentration; and/or (d) diverts or redirects glucose metabolites out of a glycolysis pathway.
Claims39
A method for treatment of cancer in a subject, comprising administering an immune cells population to the subject in need thereof in combination with an Interleukin-2/Interleukin-15 receptor beta gamma (IL-2/IL-15Rβγ) agonist,
- wherein the immune cell population comprises immune cells, which are genetically engineered to express or overexpress a polypeptide that:
- (a) improves glucose uptake activity;
- (b) modulates the Krebs cycle;
- (c) enhances lactate concentration;
- and/or
- (d) diverts or redirects glucose metabolites out of a glycolysis pathway.
Dependencies are inferred from the claim text.